Wednesday, November 29, 2023 10:07:39 AM
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. I think it’s got to come down a little because the stock is losing a lot of money."
Rayank
Recent CRSP News
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:45:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:45:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/21/2024 12:50:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:45:22 PM
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/21/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:45:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 09:30:50 PM
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit • GlobeNewswire Inc. • 02/15/2024 01:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 01:44:31 PM
- CRISPR Therapeutics Announces $280 Million Registered Direct Offering • GlobeNewswire Inc. • 02/13/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 11:30:54 AM
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) • GlobeNewswire Inc. • 02/13/2024 07:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 10:45:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/29/2024 09:08:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 09:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 10:45:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 10:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:11:36 PM
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia • GlobeNewswire Inc. • 01/16/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 04:36:20 PM
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM